- Home
- FCEL vs IGMS Comparison
FCEL vs IGMS Comparison
Compare FCEL & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCEL
- IGMS
- Stock Information
- Founded
- FCEL 1969
- IGMS 1993
- Country
- FCEL United States
- IGMS United States
- Employees
- FCEL N/A
- IGMS N/A
- Industry
- FCEL Industrial Machinery/Components
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- FCEL Energy
- IGMS Health Care
- Exchange
- FCEL Nasdaq
- IGMS Nasdaq
- Market Cap
- FCEL 96.7M
- IGMS 82.1M
- IPO Year
- FCEL 1992
- IGMS 2019
- Fundamental
- Price
- FCEL $4.28
- IGMS $1.13
- Analyst Decision
- FCEL Hold
- IGMS Hold
- Analyst Count
- FCEL 6
- IGMS 8
- Target Price
- FCEL $14.28
- IGMS $6.14
- AVG Volume (30 Days)
- FCEL 695.9K
- IGMS 152.8K
- Earning Date
- FCEL 06-09-2025
- IGMS 05-20-2025
- Dividend Yield
- FCEL N/A
- IGMS N/A
- EPS Growth
- FCEL N/A
- IGMS N/A
- EPS
- FCEL N/A
- IGMS N/A
- Revenue
- FCEL $114,438,000.00
- IGMS $2,679,000.00
- Revenue This Year
- FCEL $42.70
- IGMS $121.76
- Revenue Next Year
- FCEL $10.61
- IGMS $46.83
- P/E Ratio
- FCEL N/A
- IGMS N/A
- Revenue Growth
- FCEL 11.09
- IGMS 25.77
- 52 Week Low
- FCEL $3.58
- IGMS $0.92
- 52 Week High
- FCEL $30.90
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- FCEL 51.22
- IGMS 39.53
- Support Level
- FCEL $3.58
- IGMS $1.11
- Resistance Level
- FCEL $4.32
- IGMS $1.22
- Average True Range (ATR)
- FCEL 0.28
- IGMS 0.11
- MACD
- FCEL 0.11
- IGMS -0.02
- Stochastic Oscillator
- FCEL 68.42
- IGMS 5.56
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.